Complexity of cardiac amyloidosis [Complejidad de la amiloidosis cardíaca]
DOI:
https://doi.org/10.62574/rrr58f65Keywords:
amyloidosis, heart failure, cardiomyopathiesAbstract
Objective: To analyse the complexity of cardiac amyloidosis. Method: systematic review of 33 scientific articles. Results and conclusion: Cardiac amyloidosis represents an emerging and significantly underdiagnosed cause of heart failure, especially in the elderly population, where it is estimated that up to 15% of patients hospitalised for heart failure with preserved ejection fraction have this condition.
Downloads
References
Bloom MW, Gorevic PD. Cardiac Amyloidosis. Ann Intern Med. 2023;176(3):ITC33–48. doi: 10.7326/AITC202303210. PMID: 36913688.
Perlini S, Mussinelli R, Salinaro F. New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis. Curr Heart Fail Rep. 2016;13(6):267–72. doi: 10.1007/s11897-016-0311-y. PMID: 27900617.
Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528–40. doi: 10.1016/j.acvd.2013.06.051. PMID: 24070600.
Halwani O, Delgado DH. Cardiac amyloidosis: an approach to diagnosis and management. Expert Rev Cardiovasc Ther. 2010;8(7):1007–13. doi: 10.1586/erc.10.41. PMID: 20602561.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554–68. doi: 10.1093/eurheartj/ehab072. PMID: 33825853; PMCID: PMC8060056.
Esplin BL, Gertz MA. Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol. 2013;38(2):53–96. doi: 10.1016/j.cpcardiol.2012.11.002. PMID: 23337445.
Bampatsias D, Wardhere A, Maurer MS. Treatment of transthyretin cardiac amyloidosis. Curr Opin Cardiol. 2024;39(5):407–16. doi: 10.1097/HCO.0000000000001156. PMID: 38652263; PMCID: PMC11305969.
Nguyen O, Kamna D, Masri A. New therapies to treat cardiac amyloidosis. Curr Opin Cardiol. 2025;40(2):98–106. doi: 10.1097/HCO.0000000000001198. PMID: 39819772; PMCID: PMC11802289.
Laptseva N, Benz DC, Schwotzer R, Flammer AJ. Cardiac amyloidosis. Swiss Med Wkly. 2024;154:4186. doi: 10.57187/s.4186. PMID: 39571050.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Miocardiopatía amiloide por transtiretina: revisión de vanguardia del JACC. J Am Coll Cardiol. 2019;73:2872–91.
Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotipo y fenotipo de la amiloidosis cardíaca por transtiretina: THAOS (estudio de resultados de amiloide por transtiretina). J Am Coll Cardiol. 2016;68:161–72.
Ravichandran S, Lachmann HJ, Wechalekar AD. Tendencias epidemiológicas y de supervivencia en la amiloidosis 1987–2019. N Engl J Med. 2020;382:1567–8.
Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451–66.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnóstico y tratamiento de la amiloidosis cardíaca: una declaración de posición del Grupo de trabajo de la ESC sobre enfermedades del miocardio y el pericardio. Eur Heart J. 2021;42:1554–68. doi: 10.1093/eurheartj/ehab072.
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. Recomendaciones de consenso de expertos de ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI para imágenes multimodales en amiloidosis cardíaca: Parte 2 de 2-Criterios de diagnóstico y utilización adecuada. J Nucl Cardiol. 2020;27:659–73. doi: 10.1007/s12350-019-01761-5.
Halloush R, Lavrovskaya E, Mody D, Lager D, Truong L. Diagnóstico y tipificación de la amiloidosis sistémica: el papel de la biopsia por aspiración con aguja fina de la almohadilla grasa abdominal. CytoJournal. 2019.
Cantone A, Sanguettoli F, Dal Passo B, Serenelli M, Rapezzi C. El tratamiento de la amiloidosis se está perfeccionando. Eur Heart J Suppl. 2022;24:I131–I138.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tratamiento con tafamidis para pacientes con miocardiopatía amiloide por transtiretina. N Engl J Med. 2018;379:1007–16.
Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, et al. Supervivencia a largo plazo con tafamidis en pacientes con miocardiopatía amiloide por transtiretina. Circ Heart Fail. 2022;15:e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193.
Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517–35. doi: 10.1093/cvr/cvac119. PMID: 35929637; PMCID: PMC9897687.
Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2022;43(Suppl 2):595–604. doi: 10.1007/s10072-020-04889-2. PMID: 33188616; PMCID: PMC9780126.
Balciunaite G, Rimkus A, Zurauskas E, Zaremba T, Palionis D, Valeviciene N, et al. Transthyretin cardiac amyloidosis in aortic stenosis: Prevalence, diagnostic challenges, and clinical implications. Hellenic J Cardiol. 2020;61(2):92–8. doi: 10.1016/j.hjc.2019.10.004. PMID: 31740363.
Ioannou A, Patel RK, Razvi Y, Porcari A, Sinagra G, Venneri L, et al. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. Circulation. 2022;146(22):1657–70. doi: 10.1161/CIRCULATIONAHA.122.060852. PMID: 36325894; PMCID: PMC9698091.
Gonzalez-Lopez E, McPhail ED, Salas-Anton C, Dominguez F, Gertz MA, Dispenzieri A, et al. Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2024;83(11):1085–99. doi: 10.1016/j.jacc.2024.01.010. PMID: 38479957.
Dorbala S, Kijewski MF. Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future. J Nucl Med. 2023;64(Suppl 2):20S–28S. doi: 10.2967/jnumed.122.264866. PMID: 37918844.
Carroll A, Dyck PJ, de Carvalho M, Kennerson M, Reilly MM, Kiernan MC, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668–78. doi: 10.1136/jnnp-2021-327909. PMID: 35256455; PMCID: PMC9148983.
Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7–22. doi: 10.1161/CIR.0000000000000792. PMID: 32476490.
Duran JM, Borges-Neto S. Bone scintigraphy imaging and transthyretin-related (ATTR) cardiac amyloidosis: New tricks from an old tool? J Nucl Cardiol. 2023;30(1):368–70. doi: 10.1007/s12350-022-03032-2. PMID: 35869405; PMCID: PMC9984317.
Alwan L, Benz DC, Cuddy SAM, Dobner S, Shiri I, Caobelli F, et al. Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy. JACC Cardiovasc Imaging. 2024;17(2):195–211. doi: 10.1016/j.jcmg.2023.10.010. PMID: 38099914.
Arana-Achaga X, Goena-Vives C, Villanueva-Benito I, Solla-Ruiz I, Rengel Jimenez A, Gaspar TI, et al. Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo. JACC Cardiovasc Imaging. 2023;16(12):1567–80. doi: 10.1016/j.jcmg.2023.05.002. PMID: 37389511.
Korosoglou G, Giusca S, André F, Aus dem Siepen F, Nunninger P, Kristen AV, et al. Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms. Vasc Health Risk Manag. 2021;17:661–73. doi: 10.2147/VHRM.S295376. PMID: 34720583; PMCID: PMC8550552.
Stern LK, Patel J. Cardiac Amyloidosis Treatment. Methodist Debakey Cardiovasc J. 2022;18(2):59–72. doi: 10.14797/mdcvj.1050. PMID: 35414852; PMCID: PMC8932359.
Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390(2):132–42. doi: 10.1056/NEJMoa2305434. PMID: 38197816.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 María Gabriela Balarezo-García, Diego Armando Suárez-Páez, Sebastián Oswaldo Paredes-Tobar, Elio Joel Palma-Coque (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
